TE
AVBP icon

Tema ETFs’s ArriVent BioPharma AVBP Stock Holding History

Tema ETFs’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
+57,034
New +$1.68M 0.06% 187
2026
Q1 		– Sell
-32,007
Closed -$644K – 589
2025
Q4 		$644K Buy
+32,007
New +$666K 0.05% 312

Other funds holding AVBP

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Tema ETFs's AVBP Position: Q2 2026 in Review

Tema ETFs opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 57,034 shares worth $1.98M. The stake represents 0.06% of the portfolio and ranks #187 among its holdings. This is a return to the name: Tema ETFs previously reported a position in AVBP as recently as Q4 2025.

Tema ETFs first reported a position in AVBP in Q4 2025 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Tema ETFs held 57,034 shares of ArriVent BioPharma worth $1.98M as of Q2 2026.
  • ArriVent BioPharma was a new Tema ETFs position in Q2 2026.
  • ArriVent BioPharma made up 0.06% of Tema ETFs's portfolio in Q2 2026, its #187 holding.
  • Tema ETFs first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.